Steward Partners Investment Advisory’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Steward Partners Investment Advisory’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,000	Closed	-$720	–	3427
2023 Q1	$720	Sell	2,000 -2,500	-56%	-$2.24K	﹤0.01%	3148
2022 Q4	$3.99K	Hold	4,500	–	–	﹤0.01%	2844
2022 Q3	$7K	Hold	4,500	–	–	﹤0.01%	2672
2022 Q2	$9K	Hold	4,500	–	–	﹤0.01%	2585
2022 Q1	$10K	Hold	4,500	–	–	﹤0.01%	2686
2021 Q4	$21K	Sell	4,500 -1,298	-22%	-$8.06K	﹤0.01%	2311
2021 Q3	$44K	Hold	5,798	–	–	﹤0.01%	1974
2021 Q2	$56K	Sell	5,798 -2,400	-29%	-$19.1K	﹤0.01%	3092
2021 Q1	$67.8K	Buy	8,198 +1,400	+21%	+$14.8K	﹤0.01%	1835
2020 Q4	$46K	Hold	6,798	–	–	﹤0.01%	1713
2020 Q3	$76K	Buy	6,798 +3,298	+94%	+$30.2K	﹤0.01%	1331
2020 Q2	$22K	Buy	+3,500	New	+$13.4K	﹤0.01%	1749

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Steward Partners Investment Advisory's SRNE Position: Q2 2023 in Review

Steward Partners Investment Advisory sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 2,000 shares — an estimated $720 sold.

Steward Partners Investment Advisory first reported a position in SRNE in Q2 2020 and held it in 12 quarters. The position peaked at $76K in Q3 2020. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Steward Partners Investment Advisory reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Steward Partners Investment Advisory sold 2,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $720.
Steward Partners Investment Advisory first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 12 quarters.
Steward Partners Investment Advisory's Sorrento Therapeutics, Inc. position peaked at $76K in Q3 2020.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2023, filed 14 Aug 2023.